Viewing Study NCT01101594


Ignite Creation Date: 2025-12-25 @ 1:27 AM
Ignite Modification Date: 2025-12-28 @ 10:29 PM
Study NCT ID: NCT01101594
Status: TERMINATED
Last Update Posted: 2021-08-16
First Post: 2010-03-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Sponsor: Gilead Sciences
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module